Children with lupus kidney inflammation using mycophenolate
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 8 up to (but not including) 21
- Have lupus that meets standard diagnosis criteria for systemic lupus erythematosus (SLE)
- Have a kidney biopsy within the last 90 days showing proliferative lupus nephritis (Class 3, 3/5, 4, or 4/5)
- Be taking MMF twice daily and have taken it for at least 4 days (or 8 doses)
- Be able to swallow MMF tablets/capsules and tolerate MMF as your clinician recommends
- Have a parent/guardian who can use the study smartphone app and complete questionnaires in English or Spanish
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
This trial checks how well the drug mycophenolate mofetil works in people with lupus kidney disease by measuring drug levels in the blood. It aims to help doctors adjust doses for better control of the disease.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.